| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
From the Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
|
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
The group of small round cell sarcomas in children and adolescents that is collectively referred to as the Ewing's sarcoma family of tumors (ESFT) includes morphological variants of Ewing's sarcoma and peripheral primitive neuroectodermal tumor (PNET). All ESFTs are characterized by specific chromosomal translocations. The most commonly encountered translocation, t(11;22) (q24;q12), results in the fusion of the EWS and Fli-1 genes.16 Clinical studies have shown that despite a significant initial response to conventional treatment, a high percentage of patients with ESFT suffer a recurrence at metastatic sites.16 Since the "counterattack" model suggests that the FasL may offer a survival advantage to tumors, we investigated the role of FasL in the biology of ESFT.
In this study, we show that ESFTs frequently express Fas and FasL. A significantly higher level of FasL expression in metastatic than primary ESFTs supports the theory that FasL-expressing clones survive and undergo expansion in metastatic sites. Our in vitro data demonstrate that ESFT express not only tm-FasL, but also s-FasL and release s-FasL in the media. Both tm- and s-FasL induce apoptosis in vitro. The levels of s-FasL in the media are reduced by metalloproteinase inhibitors, suggesting cleavage by a metalloproteinase. Collectively, these data support the hypothesis that there is a dynamic equilibrium between tm- and s-FasL that can be manipulated by agents such as metalloproteinase inhibitors.
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Seven previously described and one unpublished ESFT cell lines were used in this study. Specifically, the TC-71, TC-32, A4573, 5838, SK-N-MC, CHP100 (clone-S and -L), and TC-268 cell lines were shown to have the characteristic translocation and/or EWS/Fli-1 fusion gene product of the ESFT.17-20 The unpublished cell line, TC-248, was established in our laboratory from an ESFT that exhibited the typical EWS/Fli-1 fusion product as well (data not shown). The T-cell leukemia cell line Jurkat (American Type Culture Collection, Manassas, VA) was used in functional experiments. All cells except Jurkat were grown in Dulbecco's modified Eagle's medium (DMEM) (BioWhittaker, Walkersville, MD) with 100 U/ml penicillin, 100 mg/ml streptomycin and 10% fetal calf serum (FCS) (GIBCO/BRL, Gaithersburg, MD), unless stated otherwise. Jurkat cells were grown in RPMI (GIBCO/BRL) with 10% FCS and antibiotics as above.
Tissue Sections
Sections from 61 formalin-fixed paraffin-embedded tumor tissue specimens obtained from 49 patients with ESFT and stored in the files of the Laboratory of Pathology at the National Cancer Institute (NCI) were stained for FasL. Forty of these tumors were primary and 21 were metastatic. In 12 cases, primary and metastatic tumor tissue from the same patient was available for comparison. In 34 primary and 19 metastatic tumors from which additional sections were available, immunocytochemical staining for Fas receptor was performed.
Antibodies
For immunofluorescence and immunoperoxidase staining, the anti-FasL rabbit polyclonal antibodies C-20 (against the extracellular C-terminus) and Q-20 (against the intracellular N-terminus) (Santa Cruz Biotechnology, Santa Cruz, CA) were used. Both antibodies were used in the presence or absence of the corresponding blocking peptide (amino acid residues 260–279 for C-20 and residues 2–19 for Q-20, Santa Cruz) to confirm specificity of staining. The monoclonal anti-FasL antibodies clone 33 (0.25 µg/ml) (Transduction Laboratories, Lexington, KY) and G247–4 (1:500 dilution) (Pharmingen, San Diego, CA), as well as the polyclonal antibodies Ab-3 (1:100 dilution) (Oncogene Research, Cambridge, MA) and C-20 (1:500 dilution) and Q-20 (1:500 dilution) were used in the immunoblotting experiments. Both monoclonal antibodies are directed against the extracellular portion of the FasL molecule. For detection of the Fas receptor on paraffin sections, the anti-Fas rabbit antibody Ab-1 was used (Oncogene Research) in the presence or absence of its blocking peptide (amino acid residues 321–335) (Oncogene Research). The neutralizing anti-FasL antibody NOK-2 (Pharmingen) and the cytotoxic anti-Fas monoclonal CH-11 antibody (Panvera, Madison, WI) were used in the cytotoxic cell assays.
Detection of FasL Protein in ESFT Cells and Media by Immunoblotting
Cell Lysates
Cells (1 x 106) from all 9 ESFT cell lines were scraped, centrifuged briefly, and lysed for 30 minutes on ice in a lysis buffer (50 mmol/L Tris-HCl, pH 8.0, containing 120 mmol/L NaCl and 1% Igepal), supplemented with the Complete-TM mixture of proteinase inhibitors (Boehringer Mannheim, Indianapolis, IN). The samples were cleared by centrifugation (14,000 rpm for 30 minutes at 4°C) and assessed for protein concentration. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) (12%) was performed (30 µg of protein per lane) and the proteins were electroblotted onto nitrocellulose membranes. After 1 hour incubation in blocking solution (20% IgG-free normal horse serum in PBS, GIBCO/BRL), the membranes were exposed to the primary antibody overnight at 4°C. After washing in PBS, the secondary peroxidase-labeled secondary antibody (Amersham, Arlington Heights, IL) was added at 1:10,000 dilution for 40 minutes at room temperature. The proteins were visualized with the enhanced chemiluminescence (ECL) technique (Amersham). An endothelial cell lysate, provided by Transduction Laboratories as a positive control for the anti-FasL antibody clone 33, was used along with the ESFT cell lysates in our immunoblotting experiments.
Conditioned Media
Conditioned media were generated from 3 of the 9 ESFT cell lines (TC-248, TC-268 and TC-71). These lines expressed the highest levels of FasL in the cell pellets and were selected for further analysis. Following brief washing in Hanks' balanced salt solution (HBSS) (GIBCO/BRL) and a 4-hour washing in serum-free DMEM, ESFT cells were then incubated with fresh serum-free DMEM medium overnight. The overnight-conditioned media were collected and centrifuged for 5 minutes at 2,000 rpm. The supernatants were supplemented with a proteinase inhibitor cocktail of 10 µg/ml aprotinin (Sigma, St. Louis, MO), 1 mmol/L phenylmethylsulfonyl fluoride (Sigma) and 25 µmol/L leupeptin (Sigma). To increase the sensitivity of detection of s-FasL by Western blotting, the conditioned media were subjected to 50-fold concentration with Centricon-10 filters (Amicon, Beverly, MA). The concentrates were mixed with 5x Laemmli buffer, electrophoresed on 12% SDS-PAGE gels and immunoblotted with the anti-FasL monoclonal antibody G247–4 (Pharmingen) at 1:500 dilution (1 µg/ml).
Immunocytochemical Detection of FasL in ESFT Cells and Tissues
Immunofluorescence
Air-dried cytospins from cultured cells were fixed in -20°C acetone for 10 minutes. Subsequently, the cytospins were washed and blocked for 1 hour with 20% normal goat serum and 3% bovine serum albumin (Sigma) solution in PBS. The cytospins were then washed in PBS and incubated overnight at 4°C with the C-20 or Q-20 rabbit polyclonal anti-FasL antibodies at 1:100 dilution (1µg/ml), in the presence or absence of a 10-fold excess of the corresponding blocking peptide. Subsequently, the cytospins were washed in PBS and incubated with fluorescein isothiocyanate (FITC)-labeled anti-rabbit IgG (Boehringer Mannheim, Indianapolis, IN) (1:75 dilution) for 1 hour at room temperature. Fluorescent signals were visualized with a Zeiss standard fluorescence microscope equipped with an epifluorescence illuminator and FITC narrow-band filter.
Avidin Biotin Complex Peroxidase
Immunohistochemical detection of Fas and FasL was performed as previously described.21 Briefly, 5-micron paraffin sections were deparaffinized, rehydrated, and subjected to antigen retrieval by incubation in 10 mmol/L citrate buffer for 15 minutes in a microwave oven. Endogenous peroxidase activity was quenched for 30 minutes in methanol containing 0.5% H2O2. The sections were washed in PBS and blocked for 1 hour in 20% normal goat serum in PBS. The primary antibodies, anti-FasL Q-20 (0.7 µg/ml) and anti-Fas Ab-1 (2.5 µg/ml) respectively, were applied overnight in the presence or absence of a 10-fold excess of the corresponding blocking peptides. Subsequently, the sections were washed in PBS and incubated with a biotinylated anti-rabbit antibody (1:500 dilution) for 1 hour at room temperature. After washing with PBS, the sections were covered with the Vectastain Elite Avidin Biotin Complex Reagent (Vector Laboratories, CA) for 30 minutes. The peroxidase reaction was developed with 3,3'-diaminobenzidine and the slides were counterstained with methyl green. Positive staining was evaluated subjectively by two independent observers for both percentage of positive cells and intensity of staining on a scale of 1 to 3 (interobserver agreement in 95% of cases). The product of the intensity of staining and percentage of positive cells was used for final classification into grade 0 (no staining), grade 1 (0.1–0.3), grade 2 (0.4–0.6), grade 3 (0.7–1), or grade 4 (>1).
Survival and Death Assays
3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide (MTT) Colorimetric Assay
Following treatment as indicated below, the cells were incubated
with 1 mg/ml MTT (Sigma) in fresh media for 4 hours at 37°C.
Subsequently, a mixture of isopropanol and 1N HCl (24:1, v/v)
was added under vigorous pipetting to dissolve the formazan crystals.
Dye absorbance (A) in viable cells was measured at 570 nm, with 630 nm
as a reference wavelength. Cell death was estimated with the formula:
 |
Cellular DNA Fragmentation ELISA
This method, a non-radioactive analogue of the [3H]-Thymidine-DNA fragmentation assay, was used to detect apoptosis in the co-culture experiments described below. The DNA fragmentation ELISA kit (Boehringer Mannheim) was used. Target cells were labeled overnight with 5'-bromo-2'-deoxy-uridine (BrdU) according to the manufacturer's instructions and subsequently were co-cultured with effector cells. The amount of fragmented DNA in the target cells was quantified according to the manufacturer's instructions. The results were expressed as percentages of the value in control cells.
Terminal Deoxynucleotidyl Transferase-Mediated dUTP End-Labeling (TUNEL) Method
Air-dried cytospins were labeled with the in situ cell death kit-Fluorescence (Boehringer Mannheim) following the instructions of the manufacturer and were viewed with a Zeiss standard fluorescence microscope equipped with an epifluorescence illuminator and FITC narrow-band filter.
Induction of Jurkat-cell Apoptosis by ESFT: Cells and Media
ESFT Tumor Cell-Induced Apoptosis
The ability of the TC-248 and TC-32 ESFT effector cells to kill
target lymphocytes in a Fas-dependent manner was evaluated as
previously described22
with minor modifications.
Briefly, ESFT cells (5 x 105
cells/well
grown up to 90% confluency) were fixed lightly (0.6% paraformaldehyde
in PBS for 15 minutes) and, after adequate washing in HBSS, incubated
with a Jurkat cell suspension (105
cells in 400
ml DMEM supplemented with 1% calf serum, GIBCO/BRL), at an effector to
target ratio 10:1 and in the presence or absence of the FasL
neutralizing NOK-2 antibody (10 µg/ml). After a 48-hour incubation,
Jurkat cell death was evaluated with the MTT assay, as described above.
The percentage of Jurkat cell death in each well was calculated with
the equation: % cell death =
 |
ESFT Media-Induced Apoptosis
Media conditioned with TC-248 and TC-71 cells for 48 hours were
concentrated 30-fold with Centriprep-10 filters (Amicon) and
mixed with a Jurkat cell suspension at a 1:1 v:v ratio. Thus the final
concentration of media was 15-fold, much less than the 50-fold
concentration used to detect s-FasL by Western blotting. The Jurkat
cell concentration in the final sample was 1.25 x
105
cells/ml in DMEM supplemented with 1% calf
serum. Media conditioned with TC-248 and TC-71 were added in the
presence or absence of NOK-2 FasL neutralizing antibody (10 µg/ml).
Control wells consisted of Jurkat cells in fresh medium with 1% calf
serum. Percentage of Jurkat cell death in each well was evaluated with
the MTT assay and estimated with the
equation: % cell death =
 |
Assessment of Anti-Fas Antibody CH-11-Induced Apoptosis of ESFT Cells
Cells from the TC-248, TC-268, and TC-71 cell lines were grown to 70–80% confluence. Subsequently, the cells were washed in HBSS and incubated for 18 hours with the CH-11 anti-Fas antibody (500 ng/ml, in DMEM medium with 10% calf serum) at 37°C. Cells grown in the absence of CH-11 antibody were used as negative controls. The Fas-sensitive Jurkat cell line was used as a positive control. Cell survival was evaluated with the MTT assay.
Effect of Metalloproteinase Inhibitors on s-FasL Shedding in Vitro
TC-248 cells were grown in serum-containing medium for 2 days, then washed twice in HBSS and incubated for 4 hours in serum-free DMEM with the general zinc-chelating agent 1,10-phenanthroline (0.1 mmol/L, Sigma) or with one of the following metalloproteinase inhibitors: BB-3103 (10 µM, generous gift of British Biotech, Oxford, UK), TIMP-1 (1 µg/ml), and TIMP-2 (1 µg/ml). To eliminate any possible traces of pre-existing s-FasL, this medium was discarded and replaced with fresh DMEM containing the same agents as before, at the same concentrations. The final incubation was 18 hours for BB-3103, TIMP-1, and TIMP-2 and 8 hours for 1,10-phenanthroline. At the end of the incubation times, the media were collected, subjected to 50-fold concentration, and tested for s-FasL by immunoblotting, as discussed previously
Statistical Analysis
The 
2
test was used to compare numbers of
positive and negative primary versus metastatic tumors.
Intensity of staining in total number of primaries versus
total number of metastatic tumors was evaluated with a two-sided
unpaired t-test. In cases with primary and metastatic tumors
from the same patient available for comparison, the two-sided paired
t-test was used. All other comparisons were examined with
the one-factor analysis of variance repeated measures method.
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
We investigated the presence of the tm- and s-FasL in ESFT cells
and media by immunoblotting. All antibodies against FasL (G247–4,
clone 33, Ab-3, C-20, and Q-20) identified a 37–40 kd band in the cell
lysates of all 9 ESFT cell lines. This band co-migrated with the FasL
band of the control endothelial cells and corresponds to the tm-FasL
(Figure 1A
and inset).
|
. Tm-FasL was not detected in any of the media with either clone 33
or G247–4, thus ruling out cell contamination. Although both
FasL-specific monoclonal antibodies used in the immunoblotting
experiments were directed against the extracellular domain of FasL,
clone 33 stained preferentially for tm-FasL and G247–4 exhibited
higher affinity for s-FasL. Furthermore, the G247–4 antibody also
detected an additional doublet of approximately 31 kd
(Figure 1B)
that corresponds to nonglycosylated or partially
glycosylated tm-FasL.2,5 FasL is Localized on the Surface and in the Cytoplasm of ESFT Cells
Having detected the presence of tm- and s-FasL in ESFT cells by
immunoblotting, we assessed the cellular localization of these proteins
by immunofluorescence staining of acetone-fixed cytospins from the
TC-248, TC-268, and TC-71 cell lines. Both antibodies showed diffuse
cytoplasmic and paranuclear dot-like staining that was more prominent
with the C-20 (Figure 2A)
than the Q-20
antibody (Figure 2B)
. A granular pattern at the periphery of the cells,
consistent with membranous staining, was additionally observed with the
Q-20 antibody (Figure 2B)
. These data show that FasL is expressed both
on the surface and in the cytoplasm of ESFT cells. All staining was
totally abolished in the presence of the corresponding blocking peptide
that confirmed specificity (data not shown).
|
To exclude the possibility that FasL expression in ESFT is a
random trait acquired from prolonged propagation of tumor cells
in vitro, we studied the expression of FasL by
immunohistochemistry in sections of 61 primary and metastatic tumor
tissues from 49 patients. Thirty-nine of 49 patients (79.6%) were
found positive for FasL in at least one tumor specimen. Metastatic
tumors exhibited a higher incidence of staining than primary tumors.
Specifically, among the 61 tumor specimens examined, 25 of 40 (62.5%)
primary and 20 of 21 (95%) metastatic were FasL-positive. This
difference was statistically significant (P <
0.006). Metastatic tumors also exhibited a statistically significant
higher grade of staining than primary tumors (P
= 0.000467), as shown in tissue sections in Figure 3, A and B
. Positive tumor cells
demonstrated both diffuse cytoplasmic and peripheral membrane staining
in a rim-like pattern. The staining for FasL disappeared when the
antibody was applied simultaneously with the corresponding blocking
peptide.
|
. The
remaining 4 showed no change. The difference in the grade of staining
in the paired primary and metastatic tumor tissues was statistically
significant (P = 0.0086). Positive endothelial
cells within tumor tissues served as internal positive controls.
Because the apoptotic signal of FasL is transduced via the Fas
receptor, we also investigated the presence of Fas in 53 ESFT tissues,
34 of which were primary and 19 metastatic. Fas was expressed in 40
(75.47%) ESFT in toto. Specifically, 27 of the primary
(79.4%) and 13 of the metastatic (68%) tumors were found positive for
the Fas receptor (Figure 3E)
. However, the difference in the frequency
and grade of staining for the Fas receptor in primary and metastatic
ESFT was not statistically significant (P = 0.36
and P = 0.6425, respectively). Staining for Fas
disappeared when the antibody was applied simultaneously with the
corresponding blocking peptide.
The tm-FasL Is Functional
To evaluate the biological activity of the tm-FasL on the surface of ESFT cells, we used TC-248 or TC-32 cells as cytotoxic effectors in co-culture experiments with target Fas-expressing Jurkat cells. Two different assays were used for data confirmation: the MTT assay and a DNA fragmentation ELISA. Because the MTT assay is a cell viability test, the ESFT effector cells were lightly fixed to allow assessment of viability of target Jurkat cells. On the contrary, viable ESFT cells were used in the DNA fragmentation ELISA, in which quantification of specific DNA fragmentation of target cells was based on previous labeling of Jurkat cells with BrdU. With the MTT assay, Jurkat cells co-cultured with TC-248 cells exhibited 76 ± 2% cell death (mean ± SD). The Jurkat cell death was Fas/FasL-specific, because it was inhibited to 30.4 ± 0.9% in the presence of the neutralizing anti-FasL NOK-2 antibody (P < 0.000001). With the DNA fragmentation ELISA, Jurkat cells grown in the presence of TC248 cells exhibited 1721 ± 321% the amount of fragmented DNA seen in Jurkat cells grown in the absence of TC-248 cells (P < 0.000001). Treatment with NOK-2 antibody reduced the amount of fragmented DNA to 217 ± 105% of the control (P < 0.000001). Similar results were obtained for the TC-32 cell line.
The s-FasL Is Also Functional
Having demonstrated that media conditioned with ESFT
cells are positive for s-FasL, we studied whether they can induce
apoptosis in Fas-sensitive cells. To address this question we incubated
target Jurkat cells with TC-248 or TC-71 cell-conditioned media
subjected to minimal (15-fold) concentration and evaluated Jurkat cell
death with the MTT assay. Jurkat cells co-cultured with TC-248 media
exhibited a 24 ± 6.5% (mean ± SD) cell death by MTT, that
was decreased to 3.5 ± 0.4 in the presence of the neutralizing
anti-FasL NOK-2 antibody (P < 0.005). These
results were corroborated with TUNEL staining of cytospins
generated from duplicate wells. Specifically, Jurkat cells treated with
TC-248 medium showed many strongly stained apoptotic nuclei, which were
absent or scarce in nontreated Jurkat cells and in Jurkat cells treated
with TC-248 medium containing the NOK-2 neutralizing antibody (Figure 4, A
-C). Similar results were obtained
with TC-71 cell-conditioned media. These data show that s-FasL has the
ability to induce apoptosis.
|
Because TC-268, TC-248, and TC-71 cells express functional tm- and s-FasL, we investigated their sensitivity to Fas-mediated apoptosis with the cytotoxic CH-11 anti-Fas antibody. All three ESFT cell lines showed minimal or no apoptosis, in contrast to the Fas-sensitive Jurkat cells used as a positive control.
Phenanthroline and the Synthetic Metalloproteinase Inhibitor BB-3103 Reduce Levels of s-FasL in the Media
Previously reported data have shown that the shedding of s-FasL by
activated T-cells is dependent on metalloproteinase
activity.3-5
The detection of s-FasL in the
media of ESFT cells led us to the hypothesis that ESFT cells may also
have an active metalloproteinase-like enzyme that cleaves tm- to
s-FasL. To test this hypothesis we treated TC-248 cells with various
synthetic and natural tissue inhibitors of metalloproteinases. The zinc
chelating agent 1,10-phenanthroline (Figure 5A)
and the hydroxamic acid-based
metalloproteinase inhibitor BB-3103 (Figure 5B)
reduced the levels of
s-FasL in the culture supernatant. On the contrary, treatment with the
natural tissue metalloproteinase inhibitors TIMP-1 and TIMP-2 did not
result in decreased levels of s-FasL in the supernatant (Figure 5C)
.
These results suggest that in ESFT cells, FasL is cleaved into s-FasL
by a zinc-dependent metalloproteinase that is inhibited by BB-3103 but
not by TIMP-1 or TIMP-2.
|
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
FasL exists as tm-FasL and s-FasL.1,2 We detected tm-FasL in all 9 and s-FasL in all 3 ESFT cell lines studied by immunoblotting and/or immunofluorescence staining. The tm-FasL was localized in the membrane, exhibiting a coarse granular pattern, and also in the cytoplasm, as reported previously.6,7 The s-FasL was detected primarily in ESFT cell-conditioned media but also in cell pellets. Studies regarding the presence of s-FasL in human tumors have been limited. Specifically, s-FasL has been detected in cells and sera of patients with melanoma,15 in sera of patients with hematological malignancies,3,28 and in media conditioned with bleomycin-treated hepatocellular carcinoma cells.32 The biological significance of s-FasL in solid tumors is currently unknown. Because it is released in the extracellular milieu and has been reported to have apoptotic properties,2-5,28 s-FasL may induce apoptosis of activated lymphocytes beyond sites of tumor establishment, thus facilitating tumor cell propagation and successful homing of distant organs. However, the significance of the apoptotic properties of s-FasL in vivo has been recently questioned. Specifically, one study has shown that only aggregated s-FasL induces apoptosis in Jurkat cells40 and another has suggested that various cells have preferentially lower sensitivity to s- than to tm-FasL depending on their levels of Fas expression.41 We found that ESFT-conditioned media induced apoptosis in Jurkat cells at 15-fold concentration. These data support the hypothesis that s-FasL has apoptotic properties in vitro, but its apoptotic role in biological systems requires further confirmation. It has also been suggested that s-FasL may act as a negative regulator of cell death via binding to the Fas receptor and formation of Fas/s-FasL complexes, which are easily internalized, leading to secondary down-regulation of Fas.41 Alternatively, s-FasL may simply be a catabolic product of FasL by which the cell down-regulates its surface levels of FasL, thus avoiding a suicidal death. To use the Fas/FasL system to their advantage, tumor cells must acquire resistance to Fas-mediated cytotoxicity. This is accomplished by one or both of the following mechanisms: decreased expression of the Fas receptor in tumor cells15,32,33 or abrogation of transmission of the death signal.14,15 The first mechanism does not apply to ESFT because these tumors frequently express Fas in both primary and metastatic sites, as shown in this study. In that respect, ESFT cells are similar to colon carcinoma cells that are resistant to Fas-mediated apoptosis but do not lack Fas expression.14 Defective transmission of the cytotoxic signal may be partially responsible, because the 3 ESFT cell lines we studied were found to be resistant to the cytotoxic anti-Fas antibody. However, not all ESFT are resistant to Fas-mediated cytotoxicity, as we have shown in another study.42 In the nonresistant cells, down-regulation of tm-FasL by cleavage may be important to their survival.
Recent studies have indicated that the FasL in activated human T-cells
and FasL cDNA transfectants is processed by a metalloproteinase to
yield a soluble form3-5
similar to its
homologous, TNF-
43,44
that is cleaved
by a recently cloned TNF-a converting
enzyme.45,46
The processing of the TNF-precursor
is inhibited by hydroxamic acid-based synthetic metalloproteinase
inhibitors that block zinc endopeptidases,43,47
but not by exogenous TIMPs. These data suggested that a truncated
metalloproteinase to which TIMPs are less potent may be responsible for
TNF-a processing.43
In this study we show that
the tm-FasL in ESFT cells may also be cleaved into a soluble form via a
peptidase that is a metalloproteinase, since both the general zinc
chelator 1,10-phenanthroline and the more specific hydroxamic
acid-based metalloproteinase inhibitor BB-3103 inhibited the shedding
of s-FasL in the media. In agreement with the previous studies of TNF,
TIMP-1 and TIMP-2 did not inhibit the release of s-FasL, supporting
similarities between the metalloproteinases involved in cleavage of the
two molecules. Recent data have shown that TNF-a and FasL are cleaved
by distinct metalloproteinases that carry a similar active
site.41
Our data show that in solid tumors, namely ESFT, FasL may be cleaved by a metalloproteinase, because the release of s-FasL was inhibited by a metalloproteinase inhibitor (BB-3103)48,49 as previously shown in lymphoid cells with older generation metalloproteinase inhibitors of the same family, such as batimastat (BB-94) and marimastat (BB-2516).3,4,41 Batimastat and marimastat have been shown to reduce metastases and tumor growth in experimental assays and nude mice50,51 and have been used as antineoplastic agents in phase II and III trials of a wide range of human solid tumors.52-54 Their mode of action has been explained on the basis of their inhibition of extracellular matrix cleavage by metalloproteinases. However, new experimental evidence suggests that matrix metalloproteinases influence tumor progression not only via degradation of extracellular matrix, but also via growth regulation of primary and metastatic tumors.50,55 Our finding that s-FasL levels in the media are reduced by the metalloproteinase inhibitor BB-3103 suggests that metalloproteinase inhibitors may reduce tumor growth by reversing the ratio of s- and tm-FasL. This may lead to tm-FasL accumulation, as reported in lymphoid and monocytic cells treated with metalloproteinase inhibitors,4,5,41 and to tumor cell suicide in cells with a functional Fas pathway.
In conclusion, we have shown that ESFT generally express FasL and at significantly higher levels in their metastases. This suggests that FasL may help Fas-resistant tumor cells overcome the surveillance of the immune system. We have also shown that ESFT produce FasL in both transmembrane and soluble forms. The balance of these molecules may be important in tumor growth and metastasis and can be controlled by synthetic metalloproteinase inhibitors.
|
Footnotes |
|---|
Accepted for publication September 12, 1998.
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
precursor by metalloproteinases. Nature 1994, 370:555-557[Medline]
. J Leukoc Biol 1995, 57:774-777[Abstract]
. Nature 1997, 385:733-736[Medline]
from cells. Nature 1997, 385:729-733[Medline]
processing by a metalloproteinase inhibitor. Nature 1994, 370:558-561[Medline]
in lipopolysaccharide-induced priming of mouse peritoneal macrophages for enhanced nitric oxide response to lipopolysaccharide. Immunology 1997, 92:259-266[Medline]
This article has been cited by other articles:
 |
|
 |
|
  C. S. Mitsiades, V. Poulaki, G. Fanourakis, E. Sozopoulos, D. McMillin, Z. Wen, G. Voutsinas, S. Tseleni-Balafouta, and N. Mitsiades Fas signaling in thyroid carcinomas is diverted from apoptosis to proliferation. Clin. Cancer Res., June 15, 2006; 12(12): 3705 - 3712. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R. Verneris, A. Arshi, M. Edinger, M. Kornacker, Y. Natkunam, M. Karami, Y.-a. Cao, N. Marina, C. H. Contag, and R. S. Negrin Low Levels of Her2/neu Expressed by Ewing's Family Tumor Cell Lines Can Redirect Cytokine-Induced Killer Cells Clin. Cancer Res., June 15, 2005; 11(12): 4561 - 4570. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Poulaki, C. S. Mitsiades, C. McMullan, G. Fanourakis, J. Negri, A. Goudopoulou, I. X. Halikias, G. Voutsinas, S. Tseleni-Balafouta, J. W. Miller, et al. Human Retinoblastoma Cells Are Resistant to Apoptosis Induced by Death Receptors: Role of Caspase-8 Gene Silencing Invest. Ophthalmol. Vis. Sci., January 1, 2005; 46(1): 358 - 366. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Tamura, R. Nakagawa, T. Akuta, S. Okamoto, S. Hamada, H. Maeda, S. Kawabata, and T. Akaike Proapoptotic Effect of Proteolytic Activation of Matrix Metalloproteinases by Streptococcus pyogenes Thiol Proteinase (Streptococcus Pyrogenic Exotoxin B) Infect. Immun., August 1, 2004; 72(8): 4836 - 4847. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Mitsiades, C. S. Mitsiades, P. G. Richardson, V. Poulaki, Y.-T. Tai, D. Chauhan, G. Fanourakis, X. Gu, C. Bailey, M. Joseph, et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications Blood, March 15, 2003; 101(6): 2377 - 2380. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Poulaki, C. S. Mitsiades, V. Kotoula, S. Tseleni-Balafouta, A. Ashkenazi, D. A. Koutras, and N. Mitsiades Regulation of Apo2L/Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Induced Apoptosis in Thyroid Carcinoma Cells Am. J. Pathol., August 1, 2002; 161(2): 643 - 654. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Mitsiades, C. S. Mitsiades, V. Poulaki, D. Chauhan, P. G. Richardson, T. Hideshima, N. C. Munshi, S. P. Treon, and K. C. Anderson Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications Blood, May 29, 2002; 99(12): 4525 - 4530. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Mitsiades, C. S. Mitsiades, V. Poulaki, D. Chauhan, P. G. Richardson, T. Hideshima, N. Munshi, S. P. Treon, and K. C. Anderson Biologic sequelae of nuclear factor-kappa B blockade in multiple myeloma: therapeutic applications Blood, May 13, 2002; 99(11): 4079 - 4086. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Mitsiades, C. S. Mitsiades, V. Poulaki, K. C. Anderson, and S. P. Treon Intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human multiple myeloma cells Blood, March 15, 2002; 99(6): 2162 - 2171. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Zietz, U. Rumpler, M. Sturzl, and U. Lohrs Inverse Relation of Fas-Ligand and Tumor-Infiltrating Lymphocytes in Angiosarcoma : Indications of Apoptotic Tumor Counterattack Am. J. Pathol., September 1, 2001; 159(3): 963 - 970. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. S. Mitsiades, S. P. Treon, N. Mitsiades, Y. Shima, P. Richardson, R. Schlossman, T. Hideshima, and K. C. Anderson TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications Blood, August 1, 2001; 98(3): 795 - 804. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Poulaki, N. Mitsiades, M. E. Romero, and M. Tsokos Fas-mediated Apoptosis in Neuroblastoma Requires Mitochondrial Activation and Is Inhibited by FLICE Inhibitor Protein and bcl-2 Cancer Res., June 1, 2001; 61(12): 4864 - 4872. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Han, Y. Sun, S. Scott, and D. Bleich Tissue Inhibitor of Metalloproteinase-1 Prevents Cytokine-Mediated Dysfunction and Cytotoxicity in Pancreatic Islets and {beta}-cells Diabetes, May 1, 2001; 50(5): 1047 - 1055. [Abstract] [Full Text]
|
|
|
|
|
|
N. Mitsiades, V. Poulaki, C. Mitsiades, and M. Tsokos Ewing's Sarcoma Family Tumors Are Sensitive to Tumor Necrosis Factor-related Apoptosis-inducing Ligand and Express Death Receptor 4 and Death Receptor 5 Cancer Res., March 1, 2001; 61(6): 2704 - 2712. [Abstract] [Full Text]
|
|
|
|
|
|
N. Mitsiades, W.-h. Yu, V. Poulaki, M. Tsokos, and I. Stamenkovic Matrix Metalloproteinase-7-mediated Cleavage of Fas Ligand Protects Tumor Cells from Chemotherapeutic Drug Cytotoxicity Cancer Res., January 1, 2001; 61(2): 577 - 581. [Abstract] [Full Text]
|
|
|
|
|
|
N. Mitsiades, V. Poulaki, S. Tseleni-Balafouta, D. A. Koutras, and I. Stamenkovic Thyroid Carcinoma Cells Are Resistant to FAS-mediated Apoptosis But Sensitive to Tumor Necrosis Factor-related Apoptosis-inducing Ligand Cancer Res., August 1, 2000; 60(15): 4122 - 4129. [Abstract] [Full Text]
|
|
|
